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patisn~ following myocardial infarction. However, little is known about the 
prognostic value of these tests in patients with malignant ventdcular tach- 
ya#nythmias. 
Method: The deep breath test (DB) is a widely used cardiovascular reflex 
test. It measures the difiemcoe (Diff) between maximum head rate dudng 
deep inspiration and minimum heart rate during deep expiration, The test 
is nontnvaslve, straight forward and easy to perform, 36 pts (34 male, 2 
female, mean age: 52 4-12 yrs}, who had been resuscitated from ventdcular 
fibrillation underwent DB before implantation of a cardioverterldef~dllalor 
(iCD). 
Resu~: The mean heart rata dudng the pretest pedod was 75 4- 13 
beata/mlo.. Dudng deep inspiration mean heart rate increased to 84 ± 13 
beete/min and decreased after expiration to 67 4- 12 beats/rain (p = 0.001). 
18/36 (50%) lots had an abnormal DB (Diff > 15 beats/min) (group A), the 
remaining 18 demonstrated a normal test (group B). Group A and B were 
comparable with respect o ag,~, qender, underlying heart disease (CHD: 68 
vs 68%), ejection fraction (42 v-~ ,k3%), NYHA-class (class III 22 vs 27%), 
induciimTdy dudng programmed stimulation (48 vs. 54%). 
During a mean follow up of 14 4- 4 months 20/36 (56"/,) pts developed 
apprepdate shocks, 16 (89=/=) lOtS in group A, but only 4 (22°/,) lots in group B 
(p =, 0.001 ). 
Conclusion: The DB is appropriate for assessing cardiac autonomic ner- 
veus dysfunction in ICD-pattants. An abnormal DB predicts an unfavorable 
clinical outcome and indicates pecific trigger mechanisms for subsequent 
arrhythmic events. 
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The chronic stability of the detibdllation threshold (DFT) in patients (pts) with 
an aCtive pectoral defibrillation system remains still to be defined. We report 
on our experience with a single lead unipolar pectoral defibrillation system in 
52 consecutive pta dudng a follow-up eriod of 12 months. The defibrillation 
lead system consisted of a single transvenous dght ventdcular electrode 
(cathode) and the shell (anode) of an active, left poctorally implanted efibril- 
lator device (Medtronio, model 7219 C). DFT was determined in all pts using 
a binary search protocol at th~ time of implant, at ¢lischmge, after 3, 6, and 
12 months. 
Stored energy [J] Resistance [Ohm] 
At Implant: 9.8 4. 6.3 53 4. 5 
At predlscharge: 7A :t: 4.9 47 4. 6 
At 3 month: 8.34-5.9 564-6 
At 6 month: 7.9±6.1 594-7 
At I~ month: 8.8 4. 6.8 60 .~- 6 
Intmoperetively, the defibrillation success rate at 9 J, 12 J, 18 J, and 
24 d was 58%, 83%, 90%, and 98%, respectively. There was no significant 
change in stored energy atthe DFTforthe total patient population dudng a 12 
month follow-up pedod. Furthemlore, a significant dse In defibrillation energy 
requirements did not occur In a single patient throughout the observation 
paflod. 
Conclusior~e: Defibrillation thresholds remain stable over a 12 month fotiow- 
up podnd using the unipolar pectoral datibnllation lead system. This obser- 
vation has important clinical implications for future Implantable cardioverter- 
defibrillators with reduced energy outputs to ensure an adequate enet~gy 
safety margin for continued effectiveness. 
Reduced Defibrillation Thresholds With 
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A daflbdllatton energy requirement (DER) with adequate safety margins is 
required for Implantation ofa datibdllator. Many patients require antiarrhyth- 
ml¢ (AA) drugs to decrease the frequency of ICD therapies, and these drugs 
may elevate the DER. Therefore, the purpose of this study was to determine 
the effect of local endocardlal delivery of artilide, a type III AA, on the DER 
of dogs. In 11 dogs, the chest wa.~ opened and two eptcardlal defibrillation 
patches (CPI model 1.67) were placed. DER datamdnations used an up- 
down protocol. The likelihood of 50% (ED 50) and 100% (ED 100) successful 
dal!lbdllation were calculated. Five minutes were allowed to elapse between 
each Induction of ventdcular flbdllation. A transvenous lead (TVL; CPI model 
0060) with a controlled release drug delivery system attached to tha tip was 
then placed transvenously Into the apex of the right ventricle. In 6 dogs the 
deliver/system was impregnated wiat 20% artilide, and in 5 dogs no drug 
(control) was putinto the system. Thirty minutes later, the DER was deter- 
mined again. Before the TVL was positioned, the ED 50 and ED 100 were 
8.6 4- 2.7 J and 14.0 4- 2.2 J in the control animals, and 8.0 4- 2.0 J {p = 
NS ve control) and 13.3 4- 4.1 J (p = NS vs control) In the dogs tr~'~ted with 
the artillde, respectively. After positioning the TVL, the artifide ED 50 and 
ED 100 decreased to 4.8 4- 0.9 J (p = 0.0005) and 8.5 4- 3.7 J (p = 0.02), 
respectively. For the control dogs, the ED 50 and the ED 100 did not change 
significantly (6,2 4- 2.4,1, 13.0 4- 2.7J, respectively). In conclusion, artilide 
appears to decrease the acute ED 50 and ED 100 in dogs. This effect can 
be achieved with the endocar~al administration ofthis agent via a contmlisd 
release system that results in low systemic oncontmtians. 
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Background and Methods. The upper limit of vulnerability (ULV) has been 
used in clinical studies to predict he det~dllallon threshold (DFT) in patients 
with implantable delrmillators. Despite the ULV-DFT correlation, uncertainties 
about the optimal timing of the ULV determination remain, To compare the 
precise timing of the ULV for monophasic (Mo) and biphasic (Bi) shocks, 
10 isolated rabbit hearts were immersed in a tissue bath flanked by shock 
electrodes, Mo and Bi T wave shocks (overall duration 5 ms) wero randomly 
delivered uring the vulnerable pedod at shock strengths above and below 
the ULV with a 10 ms resolution for shock coupling intervals. The ULV was 
defined as the highest VF inducing shock strength. 
Resutts. The ULV showed a substantial intra-individual variation with re- 
spect to shock timing and voltage. However, in all hearts the ULV for Bi 
shocks occurred at longer coupling intervals as compared to Mo shocks (186 
4- 9 vs 173 4- 5 ms, p < 0.001). This resulted in a mere complete repolar- 
ization level (RL) at the Bi ULV (81.1 4- 7.5 vs 66.9 4- 9.0% RL, p = 0.502) 
measured by simultaneously recorded monophasic action potentials from 
different eodocardlal nd epicardial sites. As expected, the ULV voltage was 
lower for Bi than for Mo shocks (difference 44 4- 42V, p == 0.012) reflecting 
the higher defibrillation efficacy of the Bi waveform. 
Conc/uslons. The ULV for Bi shocks occurs at a more complete repelar- 
ization state as compared to Mo shocks, thereby resulting in a rightward shift 
of the ULV towards longer coupling intervals. This is important for the deter- 
mination of the ULV-DFT correlation. Our findings also explain why different 
ULV coupling intenrais with respect to the T wavo have been proposed in 
previous tudies. 
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Pdor studies have suggested that amiodarens raises defibrillation energy 
requirements (DER), however no studies have assessed the effect of plasma 
concentrations of amiodamne or desmethyl-amiodamne (OF.A) on the DER. 
We prospectively assessed the effect of amiodamne, amledamno levels, 
and DEA levels on the DER. The DER was ~termlnsd with a monophaslc 
weveform with a single transvenous lead system. Intraopet~ DER was 
determined using a step-down protocol: 25, 20,15,10, 5, 3 ano 1J. The DER 
was defined as the minimum energy that converted vantdcular fibnllatlen to 
sinus rhythm. If the DER was > 25,1, the DER was considered elevated and 
was estimated to be 30,1. Prospective data were collected In 102 lots (76 M; 
24 F}. The msan age was 02 4- 13, the moan ejection haction was 0.31 4- 
0.14. There were no ddlemncee between patients mcaiving anliedarane (n 
= 39) vs those not receiving amloderane (n = 62) in age, gender, ejection 
fraction, type of heart disease, prior coronary artery bypass sungery, body 
surface area and left voutficolar internal diastolic dimension and mass. The 
mean duration of amiodarene use was 24 4- 33 days (range: 7-181 days). 
The mean DER was 18 4- 9J. At implantation, the mean andedamne level 
was 0.3 4- 0,6 rag/L, and the mean DEA level was 0.25 4- 0.4 mg/L Pte 
receiving amiodarone had a significantly higher DEll (22 4- 10J vs 17 4- 9J, 
p = 0.01). There was no significant correlation between amiodamn~ level 
(p = 0.4) or DEA level (p = 0.1) and the DER. In conclusion, the use of 
amiederons Is associated with elevated acute DER's, regamlass of plasma 
amiodarone or DEA concentrations, and even when these concentrations 
are subtherapautic, 
